deltatrials
Terminated PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT04566484

Seamless Controlled Trial To Evaluate Safety And Immunogenicity of Chikungunya Vaccine in LatinAmerica and Asia (IVICHIK001)

A Phase II/III Adaptive Seamless Design, Randomized, Controlled Trial To Evaluate Safety And Immunogenicity of 2 Dose-Regimen of BBV87 Chikungunya Vaccine In Healthy Subjects Aged 12 to 65 Years in Latin America and Asia.

Sponsor: International Vaccine Institute

Conditions Chikungunya
Interventions BBV87 Chikungunya vaccine Normal Saline
Updated 13 times since 2020 Last updated: Jun 17, 2025 Started: Aug 1, 2021 Primary completion: Jul 19, 2022 Completion: May 31, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The founder has decided to discontinue the study for Part C. This decision is not related to any safety concerns, adverse event findings or manufacturing process changes. There were multiple delays in initiating part C

A PHASE2/PHASE3 clinical study on Chikungunya, this trial is terminated or withdrawn. The trial is conducted by International Vaccine Institute and has accumulated 13 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Oct 2020 – ~Dec 2020 · 2 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~May 2022 · 8 months · monthly snapshot~May 2022 – ~May 2023 · 12 months · monthly snapshot~May 2023 – ~Jul 2024 · 14 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~May 2025 · 8 months · monthly snapshot~May 2025 – ~Jul 2025 · 2 months · monthly snapshot~Jul 2025 – ~Sep 2025 · 2 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2/PHASE3

  2. Jul 2025 — Sep 2025 [monthly]

    Terminated PHASE2/PHASE3

    Status: Unknown → Terminated

  3. May 2025 — Jul 2025 [monthly]

    Unknown PHASE2/PHASE3

    Status: Active Not Recruiting → Unknown

  4. Sep 2024 — May 2025 [monthly]

    Active Not Recruiting PHASE2/PHASE3

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

▶ Show 8 earlier versions

  1. May 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2_PHASE3

    Status: Recruiting → Active Not Recruiting

  2. May 2022 — May 2023 [monthly]

    Recruiting PHASE2_PHASE3

  3. Sep 2021 — May 2022 [monthly]

    Recruiting PHASE2_PHASE3

    Status: Not Yet Recruiting → Recruiting

  4. Jun 2021 — Sep 2021 [monthly]

    Not Yet Recruiting PHASE2_PHASE3

  5. May 2021 — Jun 2021 [monthly]

    Not Yet Recruiting PHASE2_PHASE3

  6. Jan 2021 — May 2021 [monthly]

    Not Yet Recruiting PHASE2_PHASE3

  7. Dec 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE2_PHASE3

  8. Oct 2020 — Dec 2020 [monthly]

    Not Yet Recruiting PHASE2_PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • International Vaccine Institute
Data source: International Vaccine Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations